Epigenetic Regulation of SST Expression in Small Intestinal Neuroendocrine Tumors

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 May 24

PMID 37223009

Authors

Maria J Klomp

Julie Refardt

Peter M Van Koetsveld

Claudia Campana

Simone U Dalm

Fadime Dogan

Marie-Louise F van Velthuysen

Richard A Feelders

Wouter W de Herder

Johannes Hofland

Leo J Hofland

Affiliations

Soon will be listed here.

Abstract

Background: Somatostatin receptor type 2 (SST) expression is critical for the diagnosis and treatment of neuroendocrine tumors and is associated with improved patient survival. Recent data suggest that epigenetic changes such as DNA methylation and histone modifications play an important role in regulating SST expression and tumorigenesis of NETs. However, there are limited data on the association between epigenetic marks and SST expression in small intestinal neuroendocrine tumors (SI-NETs).

Methods: Tissue samples from 16 patients diagnosed with SI-NETs and undergoing surgical resection of the primary tumor at Erasmus MC Rotterdam were analysed for SST expression levels and epigenetic marks surrounding the SST promoter region, i.e. DNA methylation and histone modifications H3K27me3 and H3K9ac. As a control, 13 normal SI-tissue samples were included.

Results: The SI-NET samples had high SST protein and mRNA expression levels; a median (IQR) of 80% (70-95) SST-positive cells and 8.2 times elevated SST mRNA expression level compared to normal SI-tissue (p=0.0042). In comparison to normal SI-tissue, DNA methylation levels and H3K27me3 levels were significantly lower at five out of the eight targeted CpG positions and at two out of the three examined locations within the SST gene promoter region of the SI-NET samples, respectively. No differences in the level of activating histone mark H3K9ac were observed between matched samples. While no correlation was found between histone modification marks and SST expression, SST mRNA expression levels correlated negatively with DNA methylation within the SST promoter region in both normal SI-tissue and SI-NETs (p=0.006 and p=0.04, respectively).

Conclusion: SI-NETs have lower SST promoter methylation levels and lower H3K27me3 methylation levels compared to normal SI-tissue. Moreover, in contrast to the absence of a correlation with SST protein expression levels, significant negative correlations were found between SST mRNA expression level and the mean level of DNA methylation within the SST promoter region in both normal SI-tissue and SI-NET tissue. These results indicate that DNA methylation might be involved in regulating SST expression. However, the role of histone modifications in SI-NETs remains elusive.

Citing Articles

Ectopic ACTH-Dependent Cushing's Syndrome Emerging at a Late Stage of a Mixed Histology Neuroendocrine Neoplasm: A Case Report.

Meyers M, Awada A, Karfis I, tKint de Roodenbeke D, Couvert H, Hanssens C Case Rep Oncol. 2024; 17(1):1146-1156.

PMID: 39474561 PMC: 11521454. DOI: 10.1159/000540707.

Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.

Periferakis A, Tsigas G, Periferakis A, Tone C, Hemes D, Periferakis K Curr Issues Mol Biol. 2024; 46(9):9721-9759.

PMID: 39329930 PMC: 11430067. DOI: 10.3390/cimb46090578.

References

Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret J, Souque A . Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology. 2008; 149(6):3137-47. DOI: 10.1210/en.2007-1525. View

Guenter R, Aweda T, Carmona Matos D, Whitt J, Chang A, Cheng E . Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors. Cancers (Basel). 2019; 11(6). PMC: 6627607. DOI: 10.3390/cancers11060767. View

Di Domenico A, Wiedmer T, Marinoni I, Perren A . Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017; 24(9):R315-R334. DOI: 10.1530/ERC-17-0012. View

Refardt J, Hofland J, Kwadwo A, Nicolas G, Rottenburger C, Fani M . Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Rev Endocr Metab Disord. 2020; 22(3):581-594. DOI: 10.1007/s11154-020-09552-x. View

Campana C, Van Koetsveld P, Feelders R, de Herder W, Iyer A, van Velthuysen M . Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. Eur J Endocrinol. 2022; 187(3):399-411. PMC: 9346267. DOI: 10.1530/EJE-22-0339. View

Refardt J, Klomp M, Van Koetsveld P, Dogan F, Konijnenberg M, Brabander T . Effect of epigenetic treatment on SST expression in neuroendocrine tumour patients. Clin Transl Med. 2022; 12(7):e957. PMC: 9304941. DOI: 10.1002/ctm2.957. View

Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Feelders R, Lamberts S . Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. 2018; 9(19):14791-14802. PMC: 5871078. DOI: 10.18632/oncotarget.9462. View

Scarpa A . The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Ann Endocrinol (Paris). 2019; 80(3):153-158. DOI: 10.1016/j.ando.2019.04.010. View

Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J . Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clin Cancer Res. 2015; 22(1):250-8. DOI: 10.1158/1078-0432.CCR-15-0373. View

10.

Alaskhar Alhamwe B, Khalaila R, Wolf J, von Bulow V, Harb H, Alhamdan F . Histone modifications and their role in epigenetics of atopy and allergic diseases. Allergy Asthma Clin Immunol. 2018; 14:39. PMC: 5966915. DOI: 10.1186/s13223-018-0259-4. View

11.

Klomp M, Dalm S, Van Koetsveld P, Dogan F, de Jong M, Hofland L . Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [In]In-DOTATATE Uptake in NET Cells. Cancers (Basel). 2021; 13(19). PMC: 8508045. DOI: 10.3390/cancers13194905. View

12.

Klieser E, Urbas R, Stattner S, Primavesi F, Jager T, Dinnewitzer A . Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Hum Pathol. 2017; 65:41-52. DOI: 10.1016/j.humpath.2017.02.009. View

13.

Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F . Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells. Int J Mol Sci. 2018; 19(10). PMC: 6213165. DOI: 10.3390/ijms19103128. View

14.

Choi I, Estecio M, Nagano Y, Kim D, White J, Yao J . Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007; 20(7):802-10. DOI: 10.1038/modpathol.3800825. View

15.

Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch L, Holler T . H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol. 2009; 41(2):181-9. DOI: 10.1016/j.humpath.2009.08.007. View

16.

Taelman V, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu C . Upregulation of Key Molecules for Targeted Imaging and Therapy. J Nucl Med. 2016; 57(11):1805-1810. DOI: 10.2967/jnumed.115.165092. View

17.

Guenter R, Aweda T, Carmona Matos D, Jang S, Whitt J, Cheng Y . Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment. Surgery. 2019; 167(1):189-196. PMC: 8422841. DOI: 10.1016/j.surg.2019.05.092. View

18.

Jin X, Auernhammer C, Ilhan H, Lindner S, Nolting S, Maurer J . Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. J Nucl Med. 2019; 60(9):1240-1246. DOI: 10.2967/jnumed.118.224048. View

19.

Pollard J, Menda Y, Zamba K, Madsen M, ODorisio M, ODorisio T . Potential for Increasing Uptake of Radiolabeled Ga-DOTATOC and I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. Cancer Biother Radiopharm. 2021; 36(8):632-641. PMC: 8817731. DOI: 10.1089/cbr.2020.4633. View

20.

Fotouhi O, Adel Fahmideh M, Kjellman M, Sulaiman L, Hoog A, Zedenius J . Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study. Epigenetics. 2014; 9(7):987-97. PMC: 4143414. DOI: 10.4161/epi.28936. View